2022 American Transplant Congress
Impact of Biliary Reconstruction on Tacrolimus Absorption in Pediatric Liver Transplant
1Children's Hospital Colorado, Aurora, CO, 2University of Colorado, Aurora, CO
*Purpose: Tacrolimus (FK506) oral bioavailability in pediatric liver transplant recipients (LTR) is poor. Enteral FK506 is primarily absorbed in the small intestine and subject to…2022 American Transplant Congress
Post-Kidney Transplant Dementia Risk by Modifiable Risk Factors and CNIs Among Older Recipients
*Purpose: Up to 17% of older recipients develop dementia after kidney transplant (KT). While there are known modifiable risk factors for dementia among community-dwelling older…2022 American Transplant Congress
Evaluation of Different Initial Tacrolimus Dosing Regimens in Pediatric Post-Liver Transplantation
*Purpose: Tacrolimus is an immunosuppressant used in post-liver transplantation, has wide pharmacokinetic variability, particularly in pediatric patients. Therefore, this study aimed to evaluate different weight-based…2022 American Transplant Congress
Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study
Paris Transplant Group, INSERM, Paris, France
*Purpose: Conversion to belatacept after transplant seems to be safe. However, no studies have reported the long-term efficacy and safety outcomes after conversion to belatacept…2022 American Transplant Congress
Predicted Performance of Bayesian-Based Precision Dosing Software for Tacrolimus
*Purpose: Bayesian-based precision dosing software (BPDS) has been utilized for therapeutic drug monitoring to optimize medication use. However, BPDS for tacrolimus (TAC) is not routinely…2022 American Transplant Congress
Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity
Hokkaido University Hospital, Sapporo, Japan
*Purpose: In the last two decades, the short-term results for kidney transplantation (KTX) have improved owing to the use of calcineurin inhibitors (CNIs). However, long-term…2022 American Transplant Congress
Kidney Transplant Recipients Not Reaching the Expected Post-Transplant Creatinine Range Most Likely Show Calcineurin-Inhibitor Nephrotoxicity Upon Histology
1University Hospital Zürich, Zürich, Switzerland, 2University Hospital Zurich, Zürich, Switzerland
*Purpose: Very recently, our own data suggested that approximately 25% of deceased-donor kidney transplant recipients (KTRs) and 10% of living-donor KTRs don’t reach the expected…2022 American Transplant Congress
Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study
*Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…2022 American Transplant Congress
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
*Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…2022 American Transplant Congress
Meta-Analysis of the Chronic Exposure to Calcineurin Inhibitors and the Risk for Chronic and End-Stage Kidney Disease in Non-Renal Solid Organ Transplant Recipients
*Purpose: Calcineurin inhibitors (CNI) are standard of care immunosuppressants among all solid organ transplant (SOT) recipients, and the most common side effect is nephrotoxicity. There…
- 1
- 2
- 3
- …
- 16
- Next Page »